Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The impact of exogenous and nutritional lifestyle factors on ALS progression rate: a cross-sectional multicenter study.
General Neurology
P9 - Poster Session 9 (12:00 PM-1:00 PM)
6-006

We aimed to ascertain the influence of the consumption of coffee, tea, and exogenous antioxidants and pro-oxidants on ALS progression rate.
Amyotrophic lateral sclerosis (ALS) is a devastating and still untreatable motor neuron disease. The median survival time from onset ranges from 20 to 48 months, but 10–20% of ALS patients have a survival longer than ten years. The causes of ALS are unknown, but exogenous and nutritional lifestyle factors may impact the disease progression rate.  
The cross-sectional study was conducted in five Centers. We recruited 231 patients, 93 females, and 138 males; mean age was 62.4±11.1 years. According to El Escorial criteria, 68 were definite ALS, 74 probable, 52 possible and 37 suspected; 179 patients had spinal onset and 52 bulbar. Patients were categorized into three groups according to ΔFS (derived from ALSFRS-R and disease duration from onset): slow (111 patients), intermediate (75 patients) and fast progression rate (45 patients).
Coffee consumers were more in the category of slow (85%) than in the fast progression group (64%, p=0.01), whereas we did not find any difference for tea consumers (46% vs 47%). Smokers and former smokers were more in the fast than in the slow progression group (64% vs 47%), although the difference was not significant. No statistically significant difference was found for drinking status (drinkers, non-drinkers and former drinkers), and the consumption of different alcoholic beverages (red and white wine, beer and spirits).
The study shows that coffee consumption might have a possible protective effect on ALS progression. Effects of antioxidative substances, such as coffee, could be a clue to understand the pathogenesis of ALS progression and suggest possible interventions. 
Authors/Disclosures
Andrei Ivashynka, MD, PhD (Hospital Moriggia Pelascini)
PRESENTER 		Dr. Ivashynka has nothing to disclose.
Aliona Cucovici (University of Foggia) Dr. Cucovici has nothing to disclose.
Vitalie S. Lisnic, MD (State University of Medicine and Pharmacy) No disclosure on file
No disclosure on file
No disclosure on file
Maurizio Leone, MD Dr. Leone has nothing to disclose.